Castagna Alberto, Ruotolo Giovanni, Manzo Ciro
Azienda Sanitaria Provinciale Catanzaro, Primary Care Departiment, Center for Cognitive Disorders and Dementia Catanzaro Italy.
Geriatric Unit General Hospital Azienda Ospedaliera Pugliese-Ciaccio di Catanzaro Catanzaro Italy.
Aging Med (Milton). 2020 Dec 25;4(1):53-57. doi: 10.1002/agm2.12140. eCollection 2021 Mar.
Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti-inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID-19 pandemic. However, HCQ can cause QT interval prolongation. The current therapies used in COVID-19 are changing as the pandemic develops. The aim of this article is to promote a validated risk score for QT prolongation in multidimensional assessment of COVID-19 patients, especially in elderly and polypathological patients.
羟氯喹啉（HCQ）是一种抗疟药物，也具有抗炎和抗病毒作用。由于其作用机制以及在当前新冠疫情期间可能的潜在用途，HCQ的抗病毒作用一直是许多研究人员关注的焦点。然而，HCQ可导致QT间期延长。随着疫情发展，目前用于新冠的治疗方法也在不断变化。本文旨在推广一种经过验证的用于新冠患者多维评估中QT间期延长的风险评分，尤其是针对老年患者和患有多种疾病的患者。
